General Information of the Ferroptosis Regulator (ID: REG10497)
Regulator Name Heat shock cognate 71 kDa protein (HSPA8)
Synonyms
Heat shock 70 kDa protein 8; Lipopolysaccharide-associated protein 1
    Click to Show/Hide
Gene Name HSPA8
Gene ID 3312
Regulator Type Protein coding
Uniprot ID P11142
Sequence
MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVA
MNPTNTVFDAKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKVQVEYKGETKSFYPEEVS
SMVLTKMKEIAEAYLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTAAA
IAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVNH
FIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGIDFYTSITRA
RFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELN
KSINPDEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTI
PTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAPRGVPQIEVTFDI
DANGILNVSAVDKSTGKENKITITNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKN
SLESYAFNMKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFEHQQKELE
KVCNPIITKLYQSAGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD

    Click to Show/Hide
Family Heat shock protein 70 family
Function
Molecular chaperone implicated in a wide variety of cellular processes, including protection of the proteome from stress, folding and transport of newly synthesized polypeptides, chaperone-mediated autophagy, activation of proteolysis of misfolded proteins and the formation and dissociation of protein complexes. Plays a pivotal role in the protein quality control system, ensuring the correct folding of proteins, the re-folding of misfolded proteins and controlling the targeting of proteins for subsequent degradation. This is achieved through cycles of ATP binding, ATP hydrolysis and ADP release, mediated by co-chaperones. The co-chaperones have been shown to not only regulate different steps of the ATPase cycle of HSP70, but they also have an individual specificity such that one co-chaperone may promote folding of a substrate while another may promote degradation. The affinity of HSP70 for polypeptides is regulated by its nucleotide bound state. In the ATP- bound form, it has a low affinity for substrate proteins. However, upon hydrolysis of the ATP to ADP, it undergoes a conformational change that increases its affinity for substrate proteins. HSP70 goes through repeated cycles of ATP hydrolysis and nucleotide exchange, which permits cycles of substrate binding and release. The HSP70-associated co-chaperones are of three types: J-domain co-chaperones HSP40s (stimulate ATPase hydrolysis by HSP70), the nucleotide exchange factors (NEF) such as BAG1/2/3 (facilitate conversion of HSP70 from the ADP- bound to the ATP-bound state thereby promoting substrate release), and the TPR domain chaperones such as HOPX and STUB1. Plays a critical role in mitochondrial import, delivers preproteins to the mitochondrial import receptor TOMM70. Acts as a repressor of transcriptional activation. Inhibits the transcriptional coactivator activity of CITED1 on Smad-mediated transcription. Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. May have a scaffolding role in the spliceosome assembly as it contacts all other components of the core complex. Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Substrate recognition component in chaperone-mediated autophagy (CMA), a selective protein degradation process that mediates degradation of proteins with a -KFERQ motif: HSPA8/HSC70 specifically recognizes and binds cytosolic proteins bearing a -KFERQ motif and promotes their recruitment to the surface of the lysosome where they bind to lysosomal protein LAMP2. KFERQ motif- containing proteins are eventually transported into the lysosomal lumen where they are degraded. Participates in the ER-associated degradation (ERAD) quality control pathway in conjunction with J domain-containing co- chaperones and the E3 ligase STUB1. Interacts with VGF-derived peptide TLQP-21.

    Click to Show/Hide
HGNC ID
HGNC:5241
KEGG ID hsa:3312
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
HSPA8 can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [1]
Responsed Disease Injury of intra-abdominal organs ICD-11: NB91
Responsed Drug Rifampicin Investigative
Pathway Response Fatty acid metabolism hsa01212
Autophagy hsa04140
Cell Process Cell ferroptosis
Cell autophagy
In Vitro Model
Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
AML12 cells Normal Mus musculus CVCL_0140
In Vivo Model
Male C57BL/6 mice (8-10 weeks old and weighing 20-25 g) were purchased from Hunan Experimental Animal Center (Changsha, China). All animals were housed in a 12/12h light/dark cycle and given free access to water and food. All experimental procedures were conducted in accordance with the institutional guidelines for animal care. After a minimum of 7 days of acclimation, the mice were randomly divided into five groups. DILI model group was given rifampicin (350 mg/kg) that was dissolved in saline by gavage daily for 14 days, and the same volume of saline was given as the control. Meanwhile, the other three groups were given the same volume of rifampicin to establish drug liver injury model, and treated with different compounds in the second week as follows: ferrostatin 1 (0.6 mg/kg) was injected into the tail vein every day after 2 h of rifampicin administration; geldanamycin (HSP90 inhibitor) (0.75 mg/kg) was intraperitoneally injected 2 h after rifampicin daily; 3-methyladenine (autophagy inhibitor) (15 mg/kg) was injected into tail vein 2 h after rifampicin every day. After 2 weeks of administration, serum was collected, and then mice were sacrificed by cervical dislocation. After that, liver tissue was taken for different treatments and used for reserve.

    Click to Show/Hide
Response regulation Inhibition of HSPA8 by rifampicin contributes to ferroptosis via enhancing autophagy. The present study highlights the crucial roles of the HSPA8 and autophagy in ferroptotic cell death driving by rifampicin, particularly illumines multiple promising regulatory nodes for therapeutic interventions in diseases involving anti-tuberculosis drug-induced liver injury (AT-DILI).
Injury of intra-abdominal organs [ICD-11: NB91]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [1]
Target Regulator Heat shock cognate 71 kDa protein (HSPA8) Protein coding
Responsed Drug Rifampicin Investigative
Pathway Response Fatty acid metabolism hsa01212
Autophagy hsa04140
Cell Process Cell ferroptosis
Cell autophagy
In Vitro Model
Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
AML12 cells Normal Mus musculus CVCL_0140
In Vivo Model
Male C57BL/6 mice (8-10 weeks old and weighing 20-25 g) were purchased from Hunan Experimental Animal Center (Changsha, China). All animals were housed in a 12/12h light/dark cycle and given free access to water and food. All experimental procedures were conducted in accordance with the institutional guidelines for animal care. After a minimum of 7 days of acclimation, the mice were randomly divided into five groups. DILI model group was given rifampicin (350 mg/kg) that was dissolved in saline by gavage daily for 14 days, and the same volume of saline was given as the control. Meanwhile, the other three groups were given the same volume of rifampicin to establish drug liver injury model, and treated with different compounds in the second week as follows: ferrostatin 1 (0.6 mg/kg) was injected into the tail vein every day after 2 h of rifampicin administration; geldanamycin (HSP90 inhibitor) (0.75 mg/kg) was intraperitoneally injected 2 h after rifampicin daily; 3-methyladenine (autophagy inhibitor) (15 mg/kg) was injected into tail vein 2 h after rifampicin every day. After 2 weeks of administration, serum was collected, and then mice were sacrificed by cervical dislocation. After that, liver tissue was taken for different treatments and used for reserve.

    Click to Show/Hide
Response regulation Inhibition of HSPA8 by rifampicin contributes to ferroptosis via enhancing autophagy. The present study highlights the crucial roles of the HSPA8 and autophagy in ferroptotic cell death driving by rifampicin, particularly illumines multiple promising regulatory nodes for therapeutic interventions in diseases involving anti-tuberculosis drug-induced liver injury (AT-DILI).
Rifampicin [Investigative]
In total 1 item(s) under this drug
Experiment 1 Reporting the Ferroptosis-centered Drug Response [1]
Drug for Ferroptosis Inducer
Response Target Unspecific Target
Responsed Disease Injury of intra-abdominal organs ICD-11: NB91
Pathway Response Fatty acid metabolism hsa01212
Autophagy hsa04140
Cell Process Cell ferroptosis
Cell autophagy
In Vitro Model
Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
AML12 cells Normal Mus musculus CVCL_0140
In Vivo Model
Male C57BL/6 mice (8-10 weeks old and weighing 20-25 g) were purchased from Hunan Experimental Animal Center (Changsha, China). All animals were housed in a 12/12h light/dark cycle and given free access to water and food. All experimental procedures were conducted in accordance with the institutional guidelines for animal care. After a minimum of 7 days of acclimation, the mice were randomly divided into five groups. DILI model group was given rifampicin (350 mg/kg) that was dissolved in saline by gavage daily for 14 days, and the same volume of saline was given as the control. Meanwhile, the other three groups were given the same volume of rifampicin to establish drug liver injury model, and treated with different compounds in the second week as follows: ferrostatin 1 (0.6 mg/kg) was injected into the tail vein every day after 2 h of rifampicin administration; geldanamycin (HSP90 inhibitor) (0.75 mg/kg) was intraperitoneally injected 2 h after rifampicin daily; 3-methyladenine (autophagy inhibitor) (15 mg/kg) was injected into tail vein 2 h after rifampicin every day. After 2 weeks of administration, serum was collected, and then mice were sacrificed by cervical dislocation. After that, liver tissue was taken for different treatments and used for reserve.

    Click to Show/Hide
Response regulation Inhibition of HSPA8 by rifampicin contributes to ferroptosis via enhancing autophagy. The present study highlights the crucial roles of the HSPA8 and autophagy in ferroptotic cell death driving by rifampicin, particularly illumines multiple promising regulatory nodes for therapeutic interventions in diseases involving anti-tuberculosis drug-induced liver injury (AT-DILI).
References
Ref 1 Inhibition of HSPA8 by rifampicin contributes to ferroptosis via enhancing autophagy. Liver Int. 2022 Dec;42(12):2889-2899. doi: 10.1111/liv.15459. Epub 2022 Oct 26.